Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Comparative Trial of Two Daclizumab Dosing Strategies Versus No Induction Treatment in Combination With Tacrolimus, Mycophenolate Mofetil, and Steroids for the Prevention of Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients

NCT00363116 is registered in ClinicalTrials.gov with University of Cincinnati as lead sponsor.

NCT NCT00363116
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00363116 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Comparative Trial of Two Daclizumab Dosing Strategies Versus No Induction Treatment in Combination With Tacrolimus, Mycophenolate Mofetil, and Steroids for the Prevention of Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients
Lead sponsor
University of Cincinnati
Phase
Phase 4
Overall status
Completed
Start date
April 30, 1999
Completion date
December 31, 2004
Enrollment
298 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

acute allograft rejection in simultaneous kidney/pancreas transplant recipients